Last edition
News about " Phase 2 SHIMMER study"
Cognition Therapeutics Secures US Patent for Zervimesine
Cognition Therapeutics secures US patent for a novel crystalline form of zervimesine, supporting large-scale manufacturing and planned registrational development for dementia with Lewy bodies.
Phase 2 SHIMMER Study | 14/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members